Introduction
As a well-characterised idiopathic generalised epileptic syndrome, juvenile myoclonic epilepsy (JME) shows marked genetic and clinical heterogeneity. Different loci at chromosomes 6p, located in vicinity of the HLA region as well as at 15q have been implicated in the expression of JME. 1, 2 Most of the patients may become seizure-free with valproate Seizure (2005) The presence of anti-ganglioside (GM1) or anti-glutamic acid decarboxylase (GAD) antibodies has been reported in association with therapy-resistant epilepsy mostly of focal origin. Our aim was to detect GM1 and GAD autoantibodies in patients with juvenile myoclonic epilepsy (JME) and to evaluate their association with rarely encountered therapy-resistant cases in this idiopathic generalised epilepsy syndrome. Methods: Ninety-six consecutive JME patients and 25 healthy normal control subjects were included to the study. We investigated anti-GM1 and anti-GAD antibodies with enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA), respectively. Results: We found anti-GM1 antibodies in one of 96 (1.04%) JME patients and in one out of 25 (4%) healthy controls, without reaching a significant difference between the titres. Anti-GAD antibodies were detected in 5.8% of the patients and in 4% of the healthy controls. Both antibodies did not have any association with therapy-resistant cases and with any other relevant parameters.
Conclusions:
The results of our pilot study suggested that anti-GM1 and anti-GAD antibodies are rare and they did not associate with therapy-resistance and other parameters in JME syndrome. # 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
(VPA) monotherapy, however, there is a subset of patients (15.5%) whose seizures do not respond to VPA. 3 Distinctive features are not clearly identified for this small refractory subgroup of JME.
The presence of autoantibodies against ganglioside (GM1), a ganglioside with monosialo group was reported in patients with refractory partial epilepsy. 4 On the other hand, two case-control studies 5, 6 demonstrated anti-glutamic acid decarboxylase (GAD) antibody positivity in uncontrolled epilepsy, apart from anecdotal case reports related on the same interesting association, which could be rather coincidental in patients with Stiff Man's syndrome. [7] [8] [9] [10] Although, this association was noted almost only for focal epilepsies, the highest concentration of anti-GAD antibody was found in a patient with JME out of the studied common epilepsy types and aetiologies of both idiopathic and symptomatic nature. 5 This finding, taken together with limited data about the mechanism of therapy-resistant course in some cases with JME, inspired us to explore the hypothesis that these autoantibodies might be associated with therapy resistance in JME.
Therefore, we designed a cross-sectional study to find the prevalence of anti-GM1 and anti-GAD autoantibodies and to evaluate their associations with rare, drug-resistant cases of JME syndrome.
Methods

Clinical analysis and serum samples
We investigated the sera from 96 consecutive JME patients and 25 age-matched normal healthy controls. The control subjects were all examined clinically to exclude any other neurological and systemic disease.
All patients and control subjects were included after obtaining their written informed consent. None of the patients had a history of any other neurological disease, insulin dependent diabetes mellitus (IDDM), stiff person syndrome (SPS) or an autoimmune disease. Serum samples were collected at the time of admission of the patients and stored at À70 8C until assayed. JME patients were diagnosed according to the criteria of the International League Against Epilepsy. 11 We defined the therapy-resistant course for JME syndrome as one or more generalized tonic-clonic seizures per year in the last 2 years or two or more myoclonic seizures per month despite adequate monotherapy with therapeutic serum levels.
All available clinical and EEG features were investigated for any correlation with the antibody responses. Possible effects of current received anti-epileptic drugs (AED) on the antibody concentrations were also investigated.
Anti-GM1 antibody assay
The presence of serum antibodies against GM1 gangliosides in IgG and IgM isotypes were determined with a standard enzyme-linked immunosorbent assay (ELISA). All serum samples were assayed in triplicate on flat-bottom wells of 96-well microtitre plates (Polysorp, Nunc, Denmark). ELISA was performed, briefly, by coating plate wells with or without 200 ng of GM1 (Sigma Chemicals, Poole, UK) in 20 ml methanol per well and evaporating to dryness. Non-specific binding sites were saturated with 150 ml 3% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for 1 h at room temperature. Then 100 ml of control and patients' serum samples, diluted as 1/100 in 3% BSA were added and incubated overnight at 4 8C. After four washes with 250 ml of 0.3% BSA in PBS, 100 ml horseradish peroxidase-conjugated goat anti-human IgG or IgM diluted as 1/1000 were added and the plates were incubated 1.5 h at room temperature (Sigma Chemicals, Poole, UK). The wells were washed as before, followed by the addition of 100 ml O-phenylendiamine dihydrochloride (OPD). After 45 min incubation, the reaction was stopped with 100 ml 4 M H 2 SO 4 solution. Optical densities (OD) were read at 450 nm with a microplate reader. We calculated ''corrected OD'' values by subtracting the blank well OD from the coated well OD for each sample.
Samples were considered as ''positive'' if their corrected OD was above 2 standard deviations (S.D.s) of the mean of 25 normal controls' measurements. Positive samples titrated by serial dilution above 1/100. The titre for each sample was assigned as the highest dilution in which the absorbance was 0.1 units greater than in the corresponding negative well.
Anti-GAD antibody assay
Anti-GAD antibodies were measured in the serum of 10 ''therapy resistant'' and randomly selected 59 JME patients as well as in same 25 normal controls. Anti-GAD antibodies were investigated by a radioimmunoassay (RIA) according to the manufacturer's instructions (GAD--Antibody Assay, Diagnostika GmBH, Germany). The positivity cut-off was set at 2 S.D. above the mean of 25 normal controls' measurements. All samples were tested in duplicate and the mean values were taken for presentation.
Random blood glucose levels were measured in all patients and controls to screen for undiagnosed IDDM. The sera of patients with elevated GAD autoantibody concentrations were tested for other autoantibodies, including pancreatic islet cell and antinuclear antibody, anti-nuclear cytoplasmic antibody (ANCA), anti-cardiolipins, lupus anti-coagulant, anti-dsDNA, thyroid microsomal and peroxisomal antibodies, anti-thyroglobulin, anti-gliadin and anti-intrinsic factor antibodies and rheumatoid factor.
Statistical analysis
Statistical calculations were performed with SPSS 10.0 software. Mann-Whitney U (MWU) test was applied to calculate the significance of differences between JME and normal controls. One-way analysis of variance (ANOVA) test was used to demonstrate any association of the AEDs with anti-GAD as well as anti-GM1 levels. Finally, linear regression test was used to compare the anti-GAD concentration versus anti-GM1 reactivity.
Results
Ninety-six consecutive JME patients followed for more than two years (mean follow-up period was 11.4 AE 7.2 years) and 25 age-matched normal healthy control subjects were enrolled in this study. Descriptive findings of all subjects were summarized in Table 1 .
For GM1 antibody, median ''corrected OD'' values of JME patients and normal controls were shown in Table 2 . We found that anti-GM1 antibodies of IgM isotype were positive in only 1 (1.04%) out of 96 JME patients and 1 out of 25 (4%) normal controls. The detected titres were 1/1600 in the JME patient and 1/800 in the control subjects. For IgG isotype, no positivity was detected in the patients as well as in normal controls (data not shown).
Anti-GAD antibody concentrations were also low in both groups without a significant difference (Table 2) . However, four patients had antibodies above cut-off value (5.8%), when the positivity was set at 2 S.D. above the mean of 25 normal controls' measurements. These 4 patients have the highest anti-GAD antibody levels (3.26, 2.05, 2.03, 1.58 U/ ml, respectively) and all had photosensitivity, except for one of them, as a common EEG characteristic. However, the JME patients with photosensitivity as a whole did not show any statistical difference in anti-GAD concentrations when compared with the main group. These four patients did not show any other difference from the main JME group with regard to the clinical features and they had benign course with VPA therapy. None of them had a family history of IDDM or any autoimmune disease. They were also tested for other given autoantibodies, all with negative results. The normal subject with a positivity against GAD antibodies has a concentration of 1.51 U/ml and we have learnt that this female subject was pregnant at the time of blood draw and did not know her condition.
We found only 10 patients with therapy-resistant course for JME syndrome according to our criteria. No significant differences could be demonstrated between these ''therapy resistant'' and ''benign'' groups of JME patients when tested for either anti-GM1 or anti-GAD autoantibodies. The anti-GAD concentrations did not correlate with GM1 antibodies.
Sixty-nine JME patients were under VPA monotherapy (group 1), and six patients were taking politherapy with two or more drug combinations such as VPA, phenobarbital, lamotrigine (group 2). The remaining 19 patients were taking either clonazepam or phenobarbital monotherapy (group 3). Two JME patients were not under anti-epileptic treatment. The subgroups according to various anti-epileptic drug treatments did not show any correlation with either GM1 or GAD antibody levels.
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Discussion
The role of anti-GM1 antibodies in the pathogenesis of epilepsy has been investigated mainly in experimental models. 12 Epileptogenic action of these antibodies directed against GM1 gangliosides was demonstrated in rats. 13 Such antibodies have been reported to increase release of GABA after depolarisation, possibly exerting a convulsant effect by interfering with kindling or inhibiting the interaction of GABA with synaptic receptors and/or transport sites. 14 In a recent clinical study, anti-GM1 antibodies were detected in four out of 64 patients with partial epilepsy. 4 A further case with refractory partial epilepsy was reported associating with anti-GM1 antibodies. 15 Our hypothesis was to test the presence of GM1 autoantibodies in therapy-resistant cases in JME, which was a generalised epileptic syndrome, being an entirely new target for screening. However, the titres of anti-GM1 autoantibodies were found very low in JME patients and not different from normal healthy controls.
GAD is localized largely to neurons and in particular to those that appear to use GABA as a neurotransmitter. 16 Recently, a mutation of GABRA1 gene (the gene encoding the alfa 1 subunit of GABA receptor) was demonstrated in an autosomal dominant form of JME. 17 Peltola et al. 6 studied the prevalence of anti-GAD antibodies in a substantial group of patients with therapy-resistant partial epilepsy and generalized epilepsy, and anti-GAD antibodies were found only in eight patients with partial epilepsy. We found low concentrations of anti-GAD autoantibodies in JME patients, which were not different from normal controls.
We could not demonstrate any relationship between GAD autoantibody titers and ''therapyresistant'' course in JME in our study. Rantala et al. 18 measured GAD antibodies in an unselected population of 114 children with different types of epilepsy, and none of the children were positive for GAD antibodies. Therefore, they concluded GAD antibody testing cannot be recommended in unselected cases of childhood epilepsy. Our results in JME syndrome support their conclusion.
Immune responses in patients with epilepsy may present a genetic coupling to epilepsy phenotype or may occur as consequence of long-term anti-epileptic treatment. VPA, the drug of choice for JME, may cause immunological problems like development of drug-induced systemic lupus erythematosus (SLE) [19] [20] [21] and lupus anti-coagulant. 22 We could not demonstrate any association of the AEDs with anti-GAD as well as anti-GM1 positivity in our pilot study.
The limitation of our study was the known imbalance between the ''therapy resistant'' and ''benign'' groups in JME (only 10% was defined as therapy resistant) related to our cross-sectional study design. Another weakness was the limited size of normal control subjects for defining the normal population levels of the investigated antibodies. Both of these points have obviously reduced the statistical power to draw definite conclusions. Nevertheless, we believe that low levels of both GM1 and GAD autoantibodies found in our study may point out that these antibodies do not play a marked role for therapy-resistance in this idiopathic generalised epileptic syndrome.
